Hipofosfatasia: perspectiva preclínica de su fisiopatología y tratamiento

Read full text Summarise with VIRAT
Authors: José Luís Millán
Cited by: 0
References: 84

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Hypophosphatasia (HPP) is a genetic disorder caused by loss-of-function mutations in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase (TNAP), an enzyme essential for physiological skeletal and dental mineralization. Disease severity ranges from life-threatening perinatal and infantile forms to milder late-onset forms manifesting in adulthood or affecting only dentition. Enzyme replacement therapy based on recombinant mineral-targeted alkaline phosphatase (asfotase alfa) has been approved for the treatment of pediatric-onset HPP and has significantly improved survival and skeletal outcomes. This narrative review summarizes the pathophysiology of hypophosphatasia and discusses advances in preclinical research, including gene therapy approaches, small-molecule inhibitors, and cell-based therapeutic strategies evaluated in experimental models.

Fields of Study & Subjects

Alkaline Phosphatase Research Studies Parathyroid Disorders and Treatments Bone and Dental Protein Studies

Publication details

Journal / source
EndoAr
Volume
2
Issue
1
Pages
52–68
Publication date
10 March 2026
Language
EN